Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Moderna, Inc. — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.4 (market cap $41.13B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Moderna, Inc. for 59 Days on average.
| IEF | MRNA | |
|---|---|---|
Market Cap | $41.13B | $78.65B |
Volume | 10,340,382 | 37,373,437 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $225.00 |
52-Week Low | $88.92 | $22.36 |
Typical Hold Time | 108 Days | 59 Days |
Enterprise Value | — | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF is trading at $89.45, up 0.38% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 52.94, while ADX indicates strong bearish momentum. Recent dividend payments of $0.31-$0.33 provide income support amid challenging bond market conditions. Key support sits at $89 with resistance at $90, creating a tight trading range.
The outlook remains cautious as Treasury yields near multi-decade highs create headwinds for bond ETFs. While current levels may offer entry points for income-focused investors, persistent inflation and Fed policy uncertainty pose significant risks. The bearish technical setup suggests continued pressure unless macroeconomic conditions improve.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
